These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 35204829)
21. IgG index of cerebrospinal fluid can reflect pathophysiology associated with Lewy bodies in Parkinson's disease. Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Mori Y; Asano M; Kanemoto M; Baba Y; Tsukie T; Ikeuchi T; Ono K J Neurol Sci; 2023 Sep; 452():120760. PubMed ID: 37544209 [TBL] [Abstract][Full Text] [Related]
24. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090 [TBL] [Abstract][Full Text] [Related]
25. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. Brockmann K; Schulte C; Deuschle C; Hauser AK; Heger T; Gasser T; Maetzler W; Berg D Parkinsonism Relat Disord; 2015 Dec; 21(12):1427-34. PubMed ID: 26475624 [TBL] [Abstract][Full Text] [Related]
34. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042 [TBL] [Abstract][Full Text] [Related]
35. Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. Ibanez L; Dube U; Saef B; Budde J; Black K; Medvedeva A; Del-Aguila JL; Davis AA; Perlmutter JS; Harari O; Benitez BA; Cruchaga C BMC Neurol; 2017 Nov; 17(1):198. PubMed ID: 29141588 [TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal α-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort. Majbour NK; Abdi IY; Dakna M; Wicke T; Lang E; Ali Moussa HY; Thomas MA; Trenkwalder C; Safieh-Garabedian B; Tokuda T; Mollenhauer B; El-Agnaf O Mov Disord; 2021 Sep; 36(9):2048-2056. PubMed ID: 33978256 [TBL] [Abstract][Full Text] [Related]
37. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients. Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563 [TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders. Hall S; Janelidze S; Surova Y; Widner H; Zetterberg H; Hansson O Sci Rep; 2018 Sep; 8(1):13276. PubMed ID: 30185816 [TBL] [Abstract][Full Text] [Related]
39. The value of cerebrospinal fluid α-synuclein and the tau/α-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. Førland MG; Tysnes OB; Aarsland D; Maple-Grødem J; Pedersen KF; Alves G; Lange J Eur J Neurol; 2020 Jan; 27(1):43-50. PubMed ID: 31293044 [TBL] [Abstract][Full Text] [Related]
40. Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. Majbour NK; Vaikath NN; van Dijk KD; Ardah MT; Varghese S; Vesterager LB; Montezinho LP; Poole S; Safieh-Garabedian B; Tokuda T; Teunissen CE; Berendse HW; van de Berg WD; El-Agnaf OM Mol Neurodegener; 2016 Jan; 11():7. PubMed ID: 26782965 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]